Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2016 | What has changed in AML treatment in the last 30 years?

Antonio Pagliuca • 4 Apr 2016
EBMT 2016
Acute Myeloid Leukemia

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Antonio Pagliuca, MD from King’s College Hospital, London, UK discusses improvements in supportive care and diagnostics for acute myeloid leukemia (AML). Further work is required to improve outcomes of high-risk patients.

More from Antonio Pagliuca

1:40
The future of immunotherapy
Antonio Pagliuca • 28 Feb 2019
1:18
Working together - CAR T-cell logistics
Antonio Pagliuca • 28 Feb 2019
1:27
CAR T-cell therapy's rapid entrance
Antonio Pagliuca • 28 Feb 2019
1:54
Reflections on an excellent EBMT 2018
Antonio Pagliuca • 17 Mar 2018

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals